Information Provided By:
Fly News Breaks for September 24, 2018
DGX
Sep 24, 2018 | 09:03 EDT
Credit Suisse analyst A.J. Rice raised his price target for Quest Diagnostics to $128 from $121 after meeting with CEO Steve Rusckowski and VP of Investor Relations Shawn Bevec. The analyst notes that management sees the clinical lab industry going through a period of disruptive change that should play to the strengths of national laboratory companies, such as Quest, at the expense of small regional labs and hospital outreach programs. Rice reiterates an Outperform rating on the shares.
News For DGX From the Last 2 Days
There are no results for your query DGX
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.